인공 장기 및 바이오닉 시장 예측 : 제품별, 재료별, 유통 채널별, 기술별, 용도별, 최종 사용자별, 지역별 분석(-2030년)

According to Stratistics MRC, the Global Artificial Organs and Bionic Market is accounted for $42.4 billion in 2024 and is expected to reach $80.7 billion by 2030 growing at a CAGR of 11.3% during the forecast period. Artificial organs are engineered devices designed to replicate the functions of natural organs, providing therapeutic solutions for individuals with organ failure or dysfunction. Bionics, on the other hand, refers to the integration of biological systems with mechanical components, often enhancing or restoring human capabilities through technology. Both fields aim to improve quality of life, with artificial organs focusing on organ replacement and bionics enhancing physical abilities, representing significant advancements in medical science and engineering.

According to the HRSA, in 2022, there were 8,895 organ transplant procedures performed on the population aged over 65 in the U.S. In 2022, 42,887 organ transplants were performed in the U.S., an increase of 3.7 percent over 2021.

Market Dynamics:

Driver:

Increasing demand for organ transplants

The growing demand for organ transplants is significantly boosting the market. Factors such as rising chronic diseases, an aging population, and a critical shortage of donor organs underscore the need for innovative solutions. Artificial organs provide vital alternatives for patients, while bionic technologies enhance mobility and functionality. This surge in demand is driving advancements aimed at improving patient outcomes and expanding the range of available treatments.

Restraint:

Regulatory challenges

Regulatory challenges in the market include stringent approval processes, ensuring safety and efficacy before products reach consumers. Navigating complex guidelines from agencies like the FDA can delay innovation and market entry. Additionally, varying regulations across countries complicate global collaboration and standardization. These hurdles can hinder the rapid development of life-saving technologies, making it essential for stakeholders to engage with regulators to streamline processes while maintaining safety standards.

Opportunity:

Growing incidence of chronic diseases

The increasing incidence of chronic diseases, such as diabetes, heart disease, and kidney failure, is driving demand in the market. As these conditions lead to organ dysfunction, the need for innovative solutions like artificial organs and bionic devices becomes more critical. This trend emphasizes the importance of technological advancements to enhance patient care, improve quality of life, and address the challenges posed by a growing population living with chronic health issues.

Threat:

Limited surgical expertise

Limited surgical expertise poses a significant challenge in the market. The complexity of implanting and managing advanced technologies requires highly specialized skills that may not be widely available, particularly in underserved regions. This shortage can lead to delays in patient access to life-saving devices and hinder the overall growth of the market. Addressing this gap through targeted training and education is crucial for enhancing surgical capabilities and improving patient outcomes.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the market by disrupting supply chains and delaying research and development projects. Hospitals prioritized acute care, leading to postponed elective surgeries, including those involving artificial devices. However, the pandemic also accelerated interest in innovative healthcare solutions, highlighting the need for advanced technologies to address chronic conditions exacerbated by the virus. This shift may drive future growth and investment in the sector as healthcare priorities evolve.

The bioengineered segment is projected to be the largest during the forecast period

The bioengineered segment is projected to account for the largest market share during the projection period due to rising chronic diseases and organ shortages. These innovations aim to mimic natural organ functions while addressing issues like organ shortage and rejection. By combining biological materials with engineering principles, bioengineered products offer the potential for personalized medicine, enhancing patient outcomes and paving the way for more effective treatments in regenerative medicine.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is expected to have the highest CAGR during the extrapolated period. They are essential for clinical trials, where new technologies are tested and refined. Furthermore, hospitals are increasingly adopting advanced artificial organs and bionic devices to improve patient outcomes, particularly for those with chronic conditions. This trend drives demand for innovative solutions, highlighting hospitals' pivotal position in advancing medical technology.

Region with largest share:

North America region is projected to account for the largest market share during the forecast period driven by advanced healthcare infrastructure, significant investments in research and development, and increasing prevalence of chronic diseases. Leading companies and innovative startups are at the forefront of technological advancements, focusing on artificial organs and bionic devices. Additionally, supportive government policies and a strong emphasis on patient care and personalized medicine are further propelling market expansion in the region.

Region with highest CAGR:

Asia Pacific is expected to register the highest growth rate over the forecast period driven by an increasing incidence of disabilities. The market encompasses various segments, including artificial organs like hearts and kidneys, as well as bionic devices such as cochlear implants and orthopedic bionics. The demand for these innovations is further fueled by collaborative efforts among healthcare institutions, universities, and private companies to enhance product offerings and improve patient outcomes

Key players in the market

Some of the key players in Artificial Organs and Bionic market include Medtronic Plc., Boston Scientific Corporation, IVIVA Medical, SynCardia Systems, LLC, Ekso Bionics, Edwards Lifesciences Corporation, ABIOMED, Berlin Heart, Cochlear Ltd., Jarvik Heart, Inc, Zimmer Biomet, Smith & Nephew, Kangaroo Health, Cyberdyne and Hanger Clinic.

Key Developments:

In May 2024, Medtronic Plc. acquired Aortix, a company specializing in advanced circulatory support technologies, to expand its portfolio in artificial organ systems. This acquisition is expected to enhance Medtronic's capabilities in providing innovative solutions for patients with severe cardiac conditions.

In April 2024, Zimmer Biomet Holdings, Inc. announced the successful completion of the world's first robotic-assisted shoulder replacement surgery using its ROSA(R) Shoulder System. The surgery was performed at Mayo Clinic by John W. Sperling, MD, MBA, Professor of Orthopedic Surgery at Mayo Clinic in Rochester, Minnesota, and a key contributor to the ROSA Shoulder development team.

Products Covered:

• Artificial Organs
• Bionic Devices

Materials Covered:

• Biomaterials
• Metals
• Polymers
• Ceramics

Distribution Channels Covered:

• Direct Sales
• Third-Party Distributors
• Online Platforms

Technologies Covered:

• Conventional
• Bioengineered
• Regenerative Medicine
• Nanotechnology-Based
• Other Technologies

Applications Covered:

• Chronic Diseases
• Trauma and Injury
• Cosmetic and Aesthetic Procedures
• Neuroprosthetics
• Other Applications

End Users Covered:

• Hospitals
• Ambulatory Surgical Centers
• Homecare Settings
• Rehabilitation Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Artificial Organs and Bionic Market, By Product

• 5.1 Introduction
• 5.2 Artificial Organs
  • 5.2.1 Artificial Pancreas
  • 5.2.2 Artificial Heart
  • 5.2.3 Artificial Lungs
  • 5.2.4 Artificial Kidney
  • 5.2.5 Artificial Liver
• 5.3 Bionic Devices
  • 5.3.1 Prosthetic Limbs
  • 5.3.2 Bionic Eyes
  • 5.3.3 Cochlear Implants
  • 5.3.4 Neural Interfaces

6 Global Artificial Organs and Bionic Market, By Material

• 6.1 Introduction
• 6.2 Biomaterials
• 6.3 Metals
• 6.4 Polymers
• 6.5 Ceramics

7 Global Artificial Organs and Bionic Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Direct Sales
• 7.3 Third-Party Distributors
• 7.4 Online Platforms

8 Global Artificial Organs and Bionic Market, By Technology

• 8.1 Introduction
• 8.2 Conventional
• 8.3 Bioengineered
• 8.4 Regenerative Medicine
• 8.5 Nanotechnology-Based
• 8.6 Other Technologies

9 Global Artificial Organs and Bionic Market, By Application

• 9.1 Introduction
• 9.2 Chronic Diseases
• 9.3 Trauma and Injury
• 9.4 Cosmetic and Aesthetic Procedures
• 9.5 Neuroprosthetics
• 9.6 Other Applications

10 Global Artificial Organs and Bionic Market, By End User

• 10.1 Introduction
• 10.2 Hospitals
• 10.3 Ambulatory Surgical Centers
• 10.4 Homecare Settings
• 10.5 Rehabilitation Centers
• 10.6 Other End Users

11 Global Artificial Organs and Bionic Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Medtronic Plc.
• 13.2 Boston Scientific Corporation
• 13.3 IVIVA Medical
• 13.4 SynCardia Systems, LLC
• 13.5 Ekso Bionics
• 13.6 Edwards Lifesciences Corporation
• 13.7 ABIOMED
• 13.8 Berlin Heart
• 13.9 Cochlear Ltd.
• 13.10 Jarvik Heart, Inc
• 13.11 Zimmer Biomet
• 13.12 Smith & Nephew
• 13.13 Kangaroo Health
• 13.14 Cyberdyne
• 13.15 Hanger Clinic